RecruitingPhase 2NCT07142291
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PhenoNet, Inc.
- Intervention
- Cromolyn Sodium (34.2 mg BID)(drug)
- Enrollment
- 105 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2028
Study locations (12)
- Honor Health Neurology - Bob Bove Neuroscience Institute, Scottsdale, Arizona, United States
- University of California San Diego, La Jolla, California, United States
- Sutter Health - California Pacific Medical Center Research Institute, San Francisco, California, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Lange Neurology, New York, New York, United States
- Thomayer University Hospital - Fakultní Thomayerova nemocnice, Prague, Czechia
- Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie, Berlin, Germany
- Michalski i Partnerzy Lekarze Spółka Partnerska, Krakow, Poland
- SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland
- Centrum Medyczne NeuroProtect (NeuroProtect Medical Center), Warsaw, Poland
- City Clinic Research, Warsaw, Poland
- University Clinical Center of Serbia, Belgrade, Serbia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07142291 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGPHASE3NCT07322003Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPrilenia